Thalia Therapeutics（THAT）株式概要N4 Pharma Plcは、がん治療、遺伝子治療、ワクチンの細胞送達を強化するためのシリカ・ナノ粒子送達システムを英国で開発している専門製薬会社である。 詳細THAT ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6リスク分析意味のある時価総額がありません ( £6M )キャッシュランウェイが1年未満である 収益が 100 万ドル未満 ( £7K )UK市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見るTHAT Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW471,153 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA471,153 investors already sharing narrativesYour Fair ValueUK£Current PriceUK£0.00678.3k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m110k2016201920222025202620282031Revenue UK£106.9kEarnings UK£15.6kAdvancedSet Fair ValueView all narrativesThalia Therapeutics Plc 競合他社Futura MedicalSymbol: AIM:FUMMarket cap: UK£2.6mNuformixSymbol: LSE:NFXMarket cap: UK£3.5mIncantheraSymbol: OFEX:INCMarket cap: UK£1.6mSareum HoldingsSymbol: AIM:SARMarket cap: UK£35.3m価格と性能株価の高値、安値、推移の概要Thalia Therapeutics過去の株価現在の株価UK£0.006752週高値UK£0.0152週安値UK£0.004ベータ0.721ヶ月の変化3.85%3ヶ月変化0%1年変化50.00%3年間の変化-53.45%5年間の変化-92.54%IPOからの変化-89.41%最新ニュースお知らせ • Jun 25Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, london ec2n 4bq United KingdomReported Earnings • Jun 24Full year 2025 earnings released: UK£0.002 loss per share (vs UK£0.003 loss in FY 2024)Full year 2025 results: UK£0.002 loss per share. Net loss: UK£1.21m (loss widened 14% from FY 2024).New Risk • Apr 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£5.62m market cap, or US$7.59m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£3.75m market cap, or US$5.04m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Feb 25+ 1 more updateNigel Theobald Steps Down as Director of N4 Pharma Plc, Effective from 24 February 2026N4 Pharma Plc announced that Nigel Theobald stepped down as director of the Company effective from 24 February 2026 to enjoy his retirement.Reported Earnings • Sep 28First half 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2024)First half 2025 results: UK£0.001 loss per share. Net loss: UK£498.6k (loss widened 9.6% from 1H 2024).最新情報をもっと見るRecent updatesお知らせ • Jun 25Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, london ec2n 4bq United KingdomReported Earnings • Jun 24Full year 2025 earnings released: UK£0.002 loss per share (vs UK£0.003 loss in FY 2024)Full year 2025 results: UK£0.002 loss per share. Net loss: UK£1.21m (loss widened 14% from FY 2024).New Risk • Apr 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£5.62m market cap, or US$7.59m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£3.75m market cap, or US$5.04m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).お知らせ • Feb 25+ 1 more updateNigel Theobald Steps Down as Director of N4 Pharma Plc, Effective from 24 February 2026N4 Pharma Plc announced that Nigel Theobald stepped down as director of the Company effective from 24 February 2026 to enjoy his retirement.Reported Earnings • Sep 28First half 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2024)First half 2025 results: UK£0.001 loss per share. Net loss: UK£498.6k (loss widened 9.6% from 1H 2024).お知らせ • Sep 22N4 Pharma Plc Announces Further Details of its Collaboration with SRI on the Targeting Delivery of RNA into Cells Using NuvecN4 Pharma plc announced further details of its collaboration with SRI on the targeted delivery of RNA into cells using Nuvec. Following detailed additional analysis, the resulting data are now shaping a new scope of work focused on utilising Nuvec for targeted treatments in oncology. The Company's collaboration combined SRI's targeting molecules with Nuvec successfully delivering therapeutic RNA ("siRNA") payloads to specific cell types, specifically non-small cell lung cancer cells. Key results: Precision targeting achieved: Nuvec particles were functionalised with a targeting molecule binding to a cell surface adhesion molecule (avb6) - a protein found at high levels in epithelial cancers such as lung, breast, prostate and pancreatic adenocarcinomas; Selective uptake confirmed: siRNA payloads were successfully delivered and active only by the targeted Nuvec particles compared to untargeted Nuvec, demonstrating that Nuvec can be directed to specific cell types; Broader validation of Nuvec: The findings strengthen the platform's potential as a differentiated delivery system for RNA therapeutics across multiple disease areas, including cancers of high unmet need such as lung and pancreatic cancers. challenges associated with the manufacturing and targeted delivery of RNA therapeutics are known to impact this market growth. Targeting RNA therapies to specific cells and tissues to maximise efficacy and reduce systemic toxicity is a holy grail for nucleic acid therapeutics developers and is challenging to achieve with established RNA delivery methods. In parallel to the successful targeting of Nuvec particles to cancer cells in collaboration with SRI, N4 Pharma has also demonstrated targeting of Nuvec to immune cells using mannose modification in its lead programme, N4 101, which is designed to be an orally delivered treatment for inflammatory bowel disease.お知らせ • Sep 19N4 Pharma Plc to Report First Half, 2025 Results on Sep 25, 2025N4 Pharma Plc announced that they will report first half, 2025 results on Sep 25, 2025New Risk • Sep 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (UK£7.3k revenue, or US$9.9k). Market cap is less than US$10m (UK£4.79m market cap, or US$6.48m).お知らせ • Jul 08N4 Pharma plc Appoints Edward Wardleas Non-Executive DirectorN4 Pharma Plc announced the appointment of Edward Wardleas a Non-Executive Director of the Company with immediate effect. Edward is joining the Board as a representative of Northern Standard Limited, which is the Company's largest shareholder. Edward brings board-level experience of strategy, corporate governance and business development. Having founded and led multiple businesses, he is currently an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and cutting-edge technologies, as well as a Senior Business Development Executive at Ironveld plc. He joined the Board of AIM-listed TheraCryf plc, the clinical stage drug development company focusing on neuropsychiatry and oncology, as a Non-Executive Director in May 2025. The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Edward James Norman Wardle, aged 34:Current Directorships/Partnerships: Theracryf plc; the Hammer Organization Limited; Otherworld Piccadilly Limited; the Dream Corporation Limited; Otherworld Dublin Limited. Past Directorships/Partnerships (Within 5 Years): Otherworld Manchester Limited; Otherworld Birmingham Limited.お知らせ • Jun 07N4 Pharma Plc, Annual General Meeting, Jun 30, 2025N4 Pharma Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, ec2n 4bq, london United Kingdomお知らせ • Jun 06N4 Pharma Plc Announces Formation of Senior Leadership TeamAs announced on 27 May 2025, N4 Pharma Plc's newly configured Board is now supported by the formation of a Senior Leadership Team, reporting to Nigel Theobald, Chief Executive Officer,comprising leading expert consultants in drug development and research, commercial strategy, and pharmaceutical manufacturing. The team is made up as follows: Dr Fiona McLaughlin - Head of Research and Development: Dr Fiona McLaughlin is a highly experienced oncology drug developer and independent consultant, bringing over 25 years of experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development. Fiona started her career at GSK and has subsequently held leadership positions in multiple biotech companies, including CSO of Avacta Therapeutics, VP New Opportunities at Algeta ASA (now Bayer), VP Translational Research at Antisoma plc and Director of Pre-clinical Development at BTG plc (now part of Boston Scientific). She is also a non-executive director of Hox Therapeutics. Fiona received a PhD from the Haematology Department at Cambridge University and has a BSc in Biochemistry from Glasgow University. Mark Edbrooke - Head of Strategy: Mark Edbrooke, PhD is an independent scientific consultant with a broad experience in pharmaceutical research and development. During 25 years at GlaxoSmithKline, he ran a transnational functional genomics department, and then set up and led GSK's therapeutic nucleic acid unit. He then joined AstraZeneca's Oncology Division for three years, working with Ionis and Moderna. Mark currently has a portfolio of clients, including UK and US-based investment companies, UK and European-based universities, and small biotechs, including being Head of Translational Research at Argonaute RNA Ltd., and on the Senior Advisory Board for Deep Genomics. Dr Simon Bennett - Commercial Director: Dr Simon Bennett is an independent consultant with over 28 years of experience in the bio-pharma industry. Over the last 15 years, Simon has worked with more than 70 clients of all sizes, from technology startups to Big Pharma, largely supporting business development and licensing, as well as technology scouting and fundraising. Simon has been involved in over 80 commercial deals and mentors and advises early-stage businesses and management teams, primarily in specialty pharma and biotech. Before moving into industry in 1997, Simon was a Wellcome Trust Research Fellow at the University of Oxford. Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC): Dr Margaret Courtney is an independent consultant with over 25 years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialisation. Margaret has worked in management positions in small biotech companies to large pharmaceutical organisations, and following on from her pharmacy degree and doctoral studies, has developed specific expertise in drug delivery systems. Currently, she is working with a range of clients and providing CMC strategic advice as well as selection and management of contract organisations.お知らせ • Apr 24N4 Pharma Plc has completed a Follow-on Equity Offering in the amount of £12.359907 million.N4 Pharma Plc has completed a Follow-on Equity Offering in the amount of £12.359907 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 142,780,350 Price\Range: £0.004 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 294,719,650 Price\Range: £0.04 Transaction Features: Subsequent Direct ListingNew Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m (UK£5.9k revenue, or US$7.7k). Market cap is less than US$10m (UK£2.02m market cap, or US$2.64m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change).New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 47% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Revenue is less than US$1m (UK£5.9k revenue, or US$7.2k). Market cap is less than US$10m (UK£2.66m market cap, or US$3.25m).お知らせ • Jan 08N4 Pharma plc Announces Board and Committees ChangesN4 Pharma Plc announced the appointment of Dr. Alastair Smith as an independent Non-Executive Director of the Company with immediate effect. In addition, David Templeton has retired as a Director of the Company with immediate effect due to personal reasons. Alastair was the founder and former Chief Executive Officer of Avacta Group plc ("Avacta"), an AIM-listed biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006. Over his tenure, Avacta grew into one of the leading AIM biotech companies comprising two divisions: a clinical stage oncology drug company advancing its proprietary pre CISIONTM tumour targeting platform and a diagnostics business executing an M&A-led growth strategy in Europe focused on healthcare professionals. Alastair joins the Company's remuneration and audit committees.お知らせ • Dec 13N4 Pharma plc Provides A Progress Update on the in Vitro Pre-Clinical Development of Its Lead Nuvec® Proof-Of-Concept Programme, N4 101N4 Pharma Plc provided a progress update on the in vitro pre-clinical development of its lead Nuvec®? proof-of-concept programme, N4 101, an oral anti-inflammatory product for the treatment of Inflammatory Bowel Disease (IBD). The size of the global RNA therapeutics market was $13.7 billion in 2023 and is expected to reach $18.0 billion by 20281. challenges associated with the manufacturing and delivery of RNA therapeutics are known to impact this market growth - challenges which N4 Pharma is addressing with its Nuvec®? technology, aiming to become an industry leading delivery platform used by multiple pharmaceutical partners. N4 Pharma's oral IBD product, N4 101, is designed to showcase the key benefits of the Nuvec®? delivery technology where other approaches struggle: i) it can straightforwardly load multiple RNA therapeutics onto the same particle, ii) it protects the payload from enzyme degradation to allow oral delivery to the gut andiii) it can be functionalised to target specific cells. The Company has completed a series of in vitro experiments which clearly demonstrate these competitive advantages. Key Highlights: The efficiency of delivery and efficacy of an siRNA and an mRNA therapeutic used to treat IBD are demonstrably enhanced when delivered by targeted Nuvec®? particles compared with untargeted delivery; A Nuvec®? formulation dual loaded with both therapeutics at the same time shows equivalent efficacy to the separate treatments; A patent has been filed reflecting the clear advantages of Nuvec®? for targeting and dual loading; and, The Company is awaiting ethics committee approval to build on these excellent in vitro data and begin an in vivo study in an appropriate animal model early in 2025 at the University of Queensland.お知らせ • Dec 04N4 Pharma Plc Announces New Patent FilingN4 Pharma Plc announce it has filed a new patent for its oral anti-inflammatoryIrritable Bowel Disease (‘IBD’) product in early pre-clinical development. The orally delivered product uses the unique capabilities of the Company's Nuvec delivery system to target the macrophage cells responsible for the inflammation associated with IBD. Each Nuvec nanoparticle contains two separate RNA, an siRNA to inhibit the production of TNF-alpha and an mRNA to promote the body's natural anti-inflammatory defenses. By delivering these RNA together locally in the gut, the symptoms of IBD can be more readily treated. The patent has been filed with the UK patent office.お知らせ • Sep 09N4 Pharma plc Announces Appointment of Michael Palfreyman as Independent Non-Executive DirectorN4 Pharma Plc announced the appointment of Dr. Michael Palfreyman as an independent Non-Executive Director of the Company with immediate effect. Dr. Palfreyman has more than four decades of successful drug discovery and development experience in several therapeutic areas with two major pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham Pharmaceuticals, now GSK) and has co-founded and developed several biotechnology companies including, among others, Co-Founder of Scriptgen (Anadys) Pharmaceuticals which was sold to Roche in 2011 for USD 230 million and Co-Founder and CSO of Amorsa Therapeutics Inc. developing novel treatments for depression and pain where he oversaw a successful USD 180 million exit. Dr. Palfreyman currently advises Cybin Inc. listed on the New York Exchange and was Chairman and COO to Adelia Therapeutics Inc. that merged in 2020 to form the current Cybin Inc. Dr. Palfreyman has served on various scientific advisory boards and has been an adviser to The Forsyth Institute, Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco Pharmaceuticals. Dr. Palfreymanis an Emeritus Fellow of the American College of Neuropsychopharmacology. He is co-inventor on 55 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters. Dr. Palfreyman joins the Company's remuneration and audit committees.New Risk • Jun 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 69% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.2m free cash flow). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Revenue is less than US$1m (UK£2.0k revenue, or US$2.5k). Market cap is less than US$10m (UK£2.17m market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).New Risk • May 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.2m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.5% per year over the past 5 years. Revenue is less than US$1m (UK£2.0k revenue, or US$2.5k). Market cap is less than US$10m (UK£1.92m market cap, or US$2.45m). Minor Risk Shareholders have been diluted in the past year (15% increase in shares outstanding).お知らせ • May 01N4 Pharma Plc, Annual General Meeting, May 23, 2024N4 Pharma Plc, Annual General Meeting, May 23, 2024, at 10:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street London United Kingdom Agenda: To consider and approve the annual report and audited accounts for the year ended 31 December 2023; to consider and approve the election of Director; to consider and approve the re-appointment of the Saffery Champness LLP as the Company's auditor; and to consider and approve any other matters.New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£1.75m market cap, or US$2.20m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding).お知らせ • Jan 08N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral VectorN4 Pharma Plc provided a further successful update on its ongoing research work into the use of Nuvec®? to enhance the performance of viral vectors. Through its research programme with the University of Brunel, the Company has demonstrated via a series of in vitro experiments that Nuvec®? can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 ("AAV8"). This follows on from earlier work where the Company showed that Nuvec®? increased transduction efficacy of a standard Adenovirus vector. Specifically, Nuvec®? was mixed with AAV8 carrying a fluorescent green protein gene and used to transduce human-like liver cells (induced pluripotent cell model). When the viral vector was complexed with Nuvec®?, transduction efficacy increased 2.5-fold compared to the AAV8 vector when used on a standalone basis. AAV8 was chosen for investigation as this virus is currently being used for products already in clinical development.お知らせ • Dec 18N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research WorkN4 Pharma Plc provided a positive update on its ongoing oral delivery research work. The Company through its research program with the University of Queensland is evaluating the potential of Nuvec to act as an oral delivery system for oligonucleotides including DNA and RNA. Experiments have now confirmed, in vivo, the successful oral administration of Nuvec loaded with a DNA plasmid for ovalbumin. The Nuvec was administered by enteric coated capsule and the contents, having been released in the intestinal lumen, were taken up by intestinal cells, with successful transfection and release of the newly synthesized ovalbumin. Specifically, the first experiment was a repeat of a study conducted earlier this year whereby an enterically coated capsule containing Nuvec loaded with an DNA plasmid for ovalbin was administered and protein expression was observed after 3 days. In this recent experiment, an additional second capsule was administered on day 3 which resulted in a much higher peak level of expression on days 4-7.お知らせ • Dec 07N4 Pharma plc Provides an Encouraging Update on Its Ongoing in Vitro Sirna Research WorkN4 Pharma Plc provide an encouraging update on its ongoing in vitro siRNA research work. The Company's double loaded siRNA work is ongoing and the Board wishes to provide an update on the progress achieved so far, as reach the end of 2023. The work to date is very encouraging and is demonstrating that Nuvec® has considerable potential to be able to knockdown two independent pathways leading to more effective cancer treatments by reducing the ability for tumour escape. For the past few months, the Company has been investigating the ability of Nuvec® nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. This is cutting edge research in the use of nanoparticles as delivery systems in oncology and consequently the Company is proceeding carefully to ensure that it gains the maximum understanding of the cellular processes involved. Using multiple different siRNA constructs has demonstrated that two separate siRNA can be loaded onto Nuvec®without changing the size or charge of Nuvec®, both parameters being essential for successful cellular uptake. The initial work on cell growth involved investigating the combination of inhibition ofEGFR (epidermal growth factor receptor) andBCL-2:(B-cell lymphoma 2) using PC-9 cancer cells. As previously announced, each siRNA when separately loaded onto Nuvec® achieved cell inhibition and an assay to measure BCL-2 had been established. Subsequent work has confirmed that the expression level of BCL-2 in PC9 cells was at the limits of detection, and consequently unlike with EGFR, a knockdown response curve could not be measured. In view of the low BCL-2 expression, the Company has been investigating alternative cellular pathways that may be inhibited using siRNA loaded alongside EGFR. The first was BRD4 (Bromodomain-containing-protein 4)a target for which inhibitors are currently being evaluated in clinical trials in uveal melanoma, leukemia and carcinoma. The second target was PLK1 (Polo Like Kinase 1), inhibitors of which are in early clinical trials for lymphoma and pancreatic cancer. Additional targets may also be explored as the Company's work progresses.New Risk • Sep 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.3m free cash flow). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.16m market cap, or US$3.94m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding).New Risk • Sep 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.51m market cap, or US$4.37m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding).お知らせ • Jul 25N4 Pharma plc Announces Executive Changes, Effect from 1 August 2023N4 Pharma Plc announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023.お知らせ • Jan 18N4 Pharma Plc Provides Oral Application UpdateN4 Pharma Plc provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec® loaded with DNA. The Company has now completed two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells. In the first study Nuvec® was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule. In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Chairman John Chiplin was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Oct 11Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman John Chiplin was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.分析記事 • Jul 06Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, N4 Pharma ( LON:N4P...分析記事 • Mar 18Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?The underwhelming performance at N4 Pharma Plc ( LON:N4P ) recently has probably not pleased shareholders. The next AGM...分析記事 • Mar 01Here's What We Think About N4 Pharma's (LON:N4P) CEO PayNigel Theobald has been the CEO of N4 Pharma Plc ( LON:N4P ) since 2017, and this article will examine the executive's...お知らせ • Feb 25N4 Pharma Plc, Annual General Meeting, Mar 24, 2021N4 Pharma Plc, Annual General Meeting, Mar 24, 2021, at 10:00 Coordinated Universal Time.お知らせ • Feb 13N4 Pharma plc Announces Notification of Intention to Grant PatentN4 Pharma Plc announced that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals. Having received the notification the next steps prior to formal grant will require UQ to confirm the particulars and translations with the EPO prior to publication of the grant after which the Patent will be validated on a country by country basis throughout Europe as determined by UQ and the Company. This process, resulting in the full grant of the Patent in each chosen territory, should take six to eight months.分析記事 • Dec 07Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. Indeed, N4 Pharma ( LON:N4P ) stock is...お知らせ • Dec 04N4 Pharma plc Provides the Following Update on Its Ongoing Research Collaboration Agreement with Nanomerics LimitedN4 Pharma Plc announced to provide the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on 11 February 2020, the Company initiated the first phase of research to test the stability of different formulations of Nuvec® loaded with a well characterised plasmid DNA. The Company reported that, in addition to not degrading the plasmid DNA, which it announced on 5 November 2020, Nuvec® formulations that had been freeze dried and then stored for 14 days either at room temperature or at four degrees Celsius, showed no significant drop in vitro transfection capability following reconstitution compared to fresh formulations. In parallel to continued work on analysing stability duration, different formulations will now be chosen to move forward into phase two of the work programme testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model.株主還元THATGB PharmaceuticalsGB 市場7D0%-2.2%-0.8%1Y50.0%6.8%17.3%株主還元を見る業界別リターン: THAT過去 1 年間で6.8 % の収益を上げたUK Pharmaceuticals業界を上回りました。リターン対市場: THAT過去 1 年間で17.3 % の収益を上げたUK市場を上回りました。価格変動Is THAT's price volatile compared to industry and market?THAT volatilityTHAT Average Weekly Movement7.8%Pharmaceuticals Industry Average Movement5.4%Market Average Movement5.1%10% most volatile stocks in GB Market10.4%10% least volatile stocks in GB Market2.6%安定した株価: THATの株価は、 UK市場と比較して過去 3 か月間で変動しています。時間の経過による変動: THATの 週次ボラティリティ は過去 1 年間で13%から8%に減少しましたが、依然としてUK株の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19793David Solomonwww.thaliatx.comN4 Pharma Plcは専門製薬会社で、英国でがん治療、遺伝子治療、ワクチンの細胞送達を強化するシリカナノ粒子送達システムを開発している。不規則な表面構造を持つシリカナノ粒子と核酸を捕捉・保護するポリエチレンイミンを提供するNuvecや、緑内障治療のために線維化遺伝子を沈黙させる独自のsiRNA配列を送達するプラットフォームLiptideを開発している。同社は1979年に設立され、英国ロンドンに本社を置いている。もっと見るThalia Therapeutics Plc 基礎のまとめThalia Therapeutics の収益と売上を時価総額と比較するとどうか。THAT 基礎統計学時価総額UK£5.62m収益（TTM）-UK£1.21m売上高(TTM)UK£7.26k773.4xP/Sレシオ-4.7xPER（株価収益率THAT は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計THAT 損益計算書（TTM）収益UK£7.26k売上原価UK£0売上総利益UK£7.26kその他の費用UK£1.21m収益-UK£1.21m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.0014グロス・マージン100.00%純利益率-16,588.77%有利子負債／自己資本比率0%THAT の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/13 08:19終値2026/08/13 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Thalia Therapeutics Plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Emma UlkerAllenby Capital Limited
お知らせ • Jun 25Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, london ec2n 4bq United Kingdom
Reported Earnings • Jun 24Full year 2025 earnings released: UK£0.002 loss per share (vs UK£0.003 loss in FY 2024)Full year 2025 results: UK£0.002 loss per share. Net loss: UK£1.21m (loss widened 14% from FY 2024).
New Risk • Apr 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£5.62m market cap, or US$7.59m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£3.75m market cap, or US$5.04m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Feb 25+ 1 more updateNigel Theobald Steps Down as Director of N4 Pharma Plc, Effective from 24 February 2026N4 Pharma Plc announced that Nigel Theobald stepped down as director of the Company effective from 24 February 2026 to enjoy his retirement.
Reported Earnings • Sep 28First half 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2024)First half 2025 results: UK£0.001 loss per share. Net loss: UK£498.6k (loss widened 9.6% from 1H 2024).
お知らせ • Jun 25Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026Thalia Therapeutics Plc, Annual General Meeting, Jul 17, 2026. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, london ec2n 4bq United Kingdom
Reported Earnings • Jun 24Full year 2025 earnings released: UK£0.002 loss per share (vs UK£0.003 loss in FY 2024)Full year 2025 results: UK£0.002 loss per share. Net loss: UK£1.21m (loss widened 14% from FY 2024).
New Risk • Apr 13New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 15% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£5.62m market cap, or US$7.59m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (55% increase in shares outstanding). Revenue is less than US$1m (UK£7.1k revenue, or US$9.5k). Market cap is less than US$10m (UK£3.75m market cap, or US$5.04m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end).
お知らせ • Feb 25+ 1 more updateNigel Theobald Steps Down as Director of N4 Pharma Plc, Effective from 24 February 2026N4 Pharma Plc announced that Nigel Theobald stepped down as director of the Company effective from 24 February 2026 to enjoy his retirement.
Reported Earnings • Sep 28First half 2025 earnings released: UK£0.001 loss per share (vs UK£0.002 loss in 1H 2024)First half 2025 results: UK£0.001 loss per share. Net loss: UK£498.6k (loss widened 9.6% from 1H 2024).
お知らせ • Sep 22N4 Pharma Plc Announces Further Details of its Collaboration with SRI on the Targeting Delivery of RNA into Cells Using NuvecN4 Pharma plc announced further details of its collaboration with SRI on the targeted delivery of RNA into cells using Nuvec. Following detailed additional analysis, the resulting data are now shaping a new scope of work focused on utilising Nuvec for targeted treatments in oncology. The Company's collaboration combined SRI's targeting molecules with Nuvec successfully delivering therapeutic RNA ("siRNA") payloads to specific cell types, specifically non-small cell lung cancer cells. Key results: Precision targeting achieved: Nuvec particles were functionalised with a targeting molecule binding to a cell surface adhesion molecule (avb6) - a protein found at high levels in epithelial cancers such as lung, breast, prostate and pancreatic adenocarcinomas; Selective uptake confirmed: siRNA payloads were successfully delivered and active only by the targeted Nuvec particles compared to untargeted Nuvec, demonstrating that Nuvec can be directed to specific cell types; Broader validation of Nuvec: The findings strengthen the platform's potential as a differentiated delivery system for RNA therapeutics across multiple disease areas, including cancers of high unmet need such as lung and pancreatic cancers. challenges associated with the manufacturing and targeted delivery of RNA therapeutics are known to impact this market growth. Targeting RNA therapies to specific cells and tissues to maximise efficacy and reduce systemic toxicity is a holy grail for nucleic acid therapeutics developers and is challenging to achieve with established RNA delivery methods. In parallel to the successful targeting of Nuvec particles to cancer cells in collaboration with SRI, N4 Pharma has also demonstrated targeting of Nuvec to immune cells using mannose modification in its lead programme, N4 101, which is designed to be an orally delivered treatment for inflammatory bowel disease.
お知らせ • Sep 19N4 Pharma Plc to Report First Half, 2025 Results on Sep 25, 2025N4 Pharma Plc announced that they will report first half, 2025 results on Sep 25, 2025
New Risk • Sep 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 14% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Revenue is less than US$1m (UK£7.3k revenue, or US$9.9k). Market cap is less than US$10m (UK£4.79m market cap, or US$6.48m).
お知らせ • Jul 08N4 Pharma plc Appoints Edward Wardleas Non-Executive DirectorN4 Pharma Plc announced the appointment of Edward Wardleas a Non-Executive Director of the Company with immediate effect. Edward is joining the Board as a representative of Northern Standard Limited, which is the Company's largest shareholder. Edward brings board-level experience of strategy, corporate governance and business development. Having founded and led multiple businesses, he is currently an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and cutting-edge technologies, as well as a Senior Business Development Executive at Ironveld plc. He joined the Board of AIM-listed TheraCryf plc, the clinical stage drug development company focusing on neuropsychiatry and oncology, as a Non-Executive Director in May 2025. The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Edward James Norman Wardle, aged 34:Current Directorships/Partnerships: Theracryf plc; the Hammer Organization Limited; Otherworld Piccadilly Limited; the Dream Corporation Limited; Otherworld Dublin Limited. Past Directorships/Partnerships (Within 5 Years): Otherworld Manchester Limited; Otherworld Birmingham Limited.
お知らせ • Jun 07N4 Pharma Plc, Annual General Meeting, Jun 30, 2025N4 Pharma Plc, Annual General Meeting, Jun 30, 2025. Location: the offices of arch law limited, huckletree bishopsgate, 8 bishopsgate, ec2n 4bq, london United Kingdom
お知らせ • Jun 06N4 Pharma Plc Announces Formation of Senior Leadership TeamAs announced on 27 May 2025, N4 Pharma Plc's newly configured Board is now supported by the formation of a Senior Leadership Team, reporting to Nigel Theobald, Chief Executive Officer,comprising leading expert consultants in drug development and research, commercial strategy, and pharmaceutical manufacturing. The team is made up as follows: Dr Fiona McLaughlin - Head of Research and Development: Dr Fiona McLaughlin is a highly experienced oncology drug developer and independent consultant, bringing over 25 years of experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical development. Fiona started her career at GSK and has subsequently held leadership positions in multiple biotech companies, including CSO of Avacta Therapeutics, VP New Opportunities at Algeta ASA (now Bayer), VP Translational Research at Antisoma plc and Director of Pre-clinical Development at BTG plc (now part of Boston Scientific). She is also a non-executive director of Hox Therapeutics. Fiona received a PhD from the Haematology Department at Cambridge University and has a BSc in Biochemistry from Glasgow University. Mark Edbrooke - Head of Strategy: Mark Edbrooke, PhD is an independent scientific consultant with a broad experience in pharmaceutical research and development. During 25 years at GlaxoSmithKline, he ran a transnational functional genomics department, and then set up and led GSK's therapeutic nucleic acid unit. He then joined AstraZeneca's Oncology Division for three years, working with Ionis and Moderna. Mark currently has a portfolio of clients, including UK and US-based investment companies, UK and European-based universities, and small biotechs, including being Head of Translational Research at Argonaute RNA Ltd., and on the Senior Advisory Board for Deep Genomics. Dr Simon Bennett - Commercial Director: Dr Simon Bennett is an independent consultant with over 28 years of experience in the bio-pharma industry. Over the last 15 years, Simon has worked with more than 70 clients of all sizes, from technology startups to Big Pharma, largely supporting business development and licensing, as well as technology scouting and fundraising. Simon has been involved in over 80 commercial deals and mentors and advises early-stage businesses and management teams, primarily in specialty pharma and biotech. Before moving into industry in 1997, Simon was a Wellcome Trust Research Fellow at the University of Oxford. Dr Margaret Courtney - Head of Chemistry, Manufacturing and Controls (CMC): Dr Margaret Courtney is an independent consultant with over 25 years of experience in transitioning active substances and drug products from the research laboratory into clinical studies and commercialisation. Margaret has worked in management positions in small biotech companies to large pharmaceutical organisations, and following on from her pharmacy degree and doctoral studies, has developed specific expertise in drug delivery systems. Currently, she is working with a range of clients and providing CMC strategic advice as well as selection and management of contract organisations.
お知らせ • Apr 24N4 Pharma Plc has completed a Follow-on Equity Offering in the amount of £12.359907 million.N4 Pharma Plc has completed a Follow-on Equity Offering in the amount of £12.359907 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 142,780,350 Price\Range: £0.004 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 294,719,650 Price\Range: £0.04 Transaction Features: Subsequent Direct Listing
New Risk • Apr 13New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 0.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (100% increase in shares outstanding). Revenue is less than US$1m (UK£5.9k revenue, or US$7.7k). Market cap is less than US$10m (UK£2.02m market cap, or US$2.64m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change).
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 47% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Earnings have declined by 0.6% per year over the past 5 years. Shareholders have been substantially diluted in the past year (47% increase in shares outstanding). Revenue is less than US$1m (UK£5.9k revenue, or US$7.2k). Market cap is less than US$10m (UK£2.66m market cap, or US$3.25m).
お知らせ • Jan 08N4 Pharma plc Announces Board and Committees ChangesN4 Pharma Plc announced the appointment of Dr. Alastair Smith as an independent Non-Executive Director of the Company with immediate effect. In addition, David Templeton has retired as a Director of the Company with immediate effect due to personal reasons. Alastair was the founder and former Chief Executive Officer of Avacta Group plc ("Avacta"), an AIM-listed biotech company established as a spin-out from Leeds University in 2005 and listed on the London Stock Exchange AIM market in 2006. Over his tenure, Avacta grew into one of the leading AIM biotech companies comprising two divisions: a clinical stage oncology drug company advancing its proprietary pre CISIONTM tumour targeting platform and a diagnostics business executing an M&A-led growth strategy in Europe focused on healthcare professionals. Alastair joins the Company's remuneration and audit committees.
お知らせ • Dec 13N4 Pharma plc Provides A Progress Update on the in Vitro Pre-Clinical Development of Its Lead Nuvec® Proof-Of-Concept Programme, N4 101N4 Pharma Plc provided a progress update on the in vitro pre-clinical development of its lead Nuvec®? proof-of-concept programme, N4 101, an oral anti-inflammatory product for the treatment of Inflammatory Bowel Disease (IBD). The size of the global RNA therapeutics market was $13.7 billion in 2023 and is expected to reach $18.0 billion by 20281. challenges associated with the manufacturing and delivery of RNA therapeutics are known to impact this market growth - challenges which N4 Pharma is addressing with its Nuvec®? technology, aiming to become an industry leading delivery platform used by multiple pharmaceutical partners. N4 Pharma's oral IBD product, N4 101, is designed to showcase the key benefits of the Nuvec®? delivery technology where other approaches struggle: i) it can straightforwardly load multiple RNA therapeutics onto the same particle, ii) it protects the payload from enzyme degradation to allow oral delivery to the gut andiii) it can be functionalised to target specific cells. The Company has completed a series of in vitro experiments which clearly demonstrate these competitive advantages. Key Highlights: The efficiency of delivery and efficacy of an siRNA and an mRNA therapeutic used to treat IBD are demonstrably enhanced when delivered by targeted Nuvec®? particles compared with untargeted delivery; A Nuvec®? formulation dual loaded with both therapeutics at the same time shows equivalent efficacy to the separate treatments; A patent has been filed reflecting the clear advantages of Nuvec®? for targeting and dual loading; and, The Company is awaiting ethics committee approval to build on these excellent in vitro data and begin an in vivo study in an appropriate animal model early in 2025 at the University of Queensland.
お知らせ • Dec 04N4 Pharma Plc Announces New Patent FilingN4 Pharma Plc announce it has filed a new patent for its oral anti-inflammatoryIrritable Bowel Disease (‘IBD’) product in early pre-clinical development. The orally delivered product uses the unique capabilities of the Company's Nuvec delivery system to target the macrophage cells responsible for the inflammation associated with IBD. Each Nuvec nanoparticle contains two separate RNA, an siRNA to inhibit the production of TNF-alpha and an mRNA to promote the body's natural anti-inflammatory defenses. By delivering these RNA together locally in the gut, the symptoms of IBD can be more readily treated. The patent has been filed with the UK patent office.
お知らせ • Sep 09N4 Pharma plc Announces Appointment of Michael Palfreyman as Independent Non-Executive DirectorN4 Pharma Plc announced the appointment of Dr. Michael Palfreyman as an independent Non-Executive Director of the Company with immediate effect. Dr. Palfreyman has more than four decades of successful drug discovery and development experience in several therapeutic areas with two major pharmaceutical companies (Marrion Meryl Dow, now Sanofi, and Beecham Pharmaceuticals, now GSK) and has co-founded and developed several biotechnology companies including, among others, Co-Founder of Scriptgen (Anadys) Pharmaceuticals which was sold to Roche in 2011 for USD 230 million and Co-Founder and CSO of Amorsa Therapeutics Inc. developing novel treatments for depression and pain where he oversaw a successful USD 180 million exit. Dr. Palfreyman currently advises Cybin Inc. listed on the New York Exchange and was Chairman and COO to Adelia Therapeutics Inc. that merged in 2020 to form the current Cybin Inc. Dr. Palfreyman has served on various scientific advisory boards and has been an adviser to The Forsyth Institute, Stanford Research Institute, NeuroNascent, MAK Scientific and Jasco Pharmaceuticals. Dr. Palfreymanis an Emeritus Fellow of the American College of Neuropsychopharmacology. He is co-inventor on 55 issued US and European patents, multiple pending patents, and has co-authored over 150 scientific articles and book chapters. Dr. Palfreyman joins the Company's remuneration and audit committees.
New Risk • Jun 10New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 69% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.2m free cash flow). Earnings have declined by 1.5% per year over the past 5 years. Shareholders have been substantially diluted in the past year (69% increase in shares outstanding). Revenue is less than US$1m (UK£2.0k revenue, or US$2.5k). Market cap is less than US$10m (UK£2.17m market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
New Risk • May 24New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of British stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.2m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.5% per year over the past 5 years. Revenue is less than US$1m (UK£2.0k revenue, or US$2.5k). Market cap is less than US$10m (UK£1.92m market cap, or US$2.45m). Minor Risk Shareholders have been diluted in the past year (15% increase in shares outstanding).
お知らせ • May 01N4 Pharma Plc, Annual General Meeting, May 23, 2024N4 Pharma Plc, Annual General Meeting, May 23, 2024, at 10:00 Coordinated Universal Time. Location: Shakespeare Martineau LLP, 6th Floor 60 Gracechurch Street London United Kingdom Agenda: To consider and approve the annual report and audited accounts for the year ended 31 December 2023; to consider and approve the election of Director; to consider and approve the re-appointment of the Saffery Champness LLP as the Company's auditor; and to consider and approve any other matters.
New Risk • Mar 30New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£1.75m market cap, or US$2.20m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (15% increase in shares outstanding).
お知らせ • Jan 08N4 Pharma plc Provides A Further Successful Update on Its Ongoing Research Work into the Use of Nuvec to Enhance the Performance of Viral VectorN4 Pharma Plc provided a further successful update on its ongoing research work into the use of Nuvec®? to enhance the performance of viral vectors. Through its research programme with the University of Brunel, the Company has demonstrated via a series of in vitro experiments that Nuvec®? can deliver increased transduction efficacy, when complexed with Adeno-Associated virus 8 ("AAV8"). This follows on from earlier work where the Company showed that Nuvec®? increased transduction efficacy of a standard Adenovirus vector. Specifically, Nuvec®? was mixed with AAV8 carrying a fluorescent green protein gene and used to transduce human-like liver cells (induced pluripotent cell model). When the viral vector was complexed with Nuvec®?, transduction efficacy increased 2.5-fold compared to the AAV8 vector when used on a standalone basis. AAV8 was chosen for investigation as this virus is currently being used for products already in clinical development.
お知らせ • Dec 18N4 Pharma Plc Provides Positive Update on its Ongoing Oral Delivery Research WorkN4 Pharma Plc provided a positive update on its ongoing oral delivery research work. The Company through its research program with the University of Queensland is evaluating the potential of Nuvec to act as an oral delivery system for oligonucleotides including DNA and RNA. Experiments have now confirmed, in vivo, the successful oral administration of Nuvec loaded with a DNA plasmid for ovalbumin. The Nuvec was administered by enteric coated capsule and the contents, having been released in the intestinal lumen, were taken up by intestinal cells, with successful transfection and release of the newly synthesized ovalbumin. Specifically, the first experiment was a repeat of a study conducted earlier this year whereby an enterically coated capsule containing Nuvec loaded with an DNA plasmid for ovalbin was administered and protein expression was observed after 3 days. In this recent experiment, an additional second capsule was administered on day 3 which resulted in a much higher peak level of expression on days 4-7.
お知らせ • Dec 07N4 Pharma plc Provides an Encouraging Update on Its Ongoing in Vitro Sirna Research WorkN4 Pharma Plc provide an encouraging update on its ongoing in vitro siRNA research work. The Company's double loaded siRNA work is ongoing and the Board wishes to provide an update on the progress achieved so far, as reach the end of 2023. The work to date is very encouraging and is demonstrating that Nuvec® has considerable potential to be able to knockdown two independent pathways leading to more effective cancer treatments by reducing the ability for tumour escape. For the past few months, the Company has been investigating the ability of Nuvec® nanoparticles to be loaded with, and deliver at the same time, two different siRNA known to inhibit relevant oncology targets. This is cutting edge research in the use of nanoparticles as delivery systems in oncology and consequently the Company is proceeding carefully to ensure that it gains the maximum understanding of the cellular processes involved. Using multiple different siRNA constructs has demonstrated that two separate siRNA can be loaded onto Nuvec®without changing the size or charge of Nuvec®, both parameters being essential for successful cellular uptake. The initial work on cell growth involved investigating the combination of inhibition ofEGFR (epidermal growth factor receptor) andBCL-2:(B-cell lymphoma 2) using PC-9 cancer cells. As previously announced, each siRNA when separately loaded onto Nuvec® achieved cell inhibition and an assay to measure BCL-2 had been established. Subsequent work has confirmed that the expression level of BCL-2 in PC9 cells was at the limits of detection, and consequently unlike with EGFR, a knockdown response curve could not be measured. In view of the low BCL-2 expression, the Company has been investigating alternative cellular pathways that may be inhibited using siRNA loaded alongside EGFR. The first was BRD4 (Bromodomain-containing-protein 4)a target for which inhibitors are currently being evaluated in clinical trials in uveal melanoma, leukemia and carcinoma. The second target was PLK1 (Polo Like Kinase 1), inhibitors of which are in early clinical trials for lymphoma and pancreatic cancer. Additional targets may also be explored as the Company's work progresses.
New Risk • Sep 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.3m free cash flow). Earnings have declined by 10% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.16m market cap, or US$3.94m). Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding).
New Risk • Sep 08New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 17% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (UK£3.51m market cap, or US$4.37m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Share price has been volatile over the past 3 months (8.5% average weekly change). Shareholders have been diluted in the past year (29% increase in shares outstanding).
お知らせ • Jul 25N4 Pharma plc Announces Executive Changes, Effect from 1 August 2023N4 Pharma Plc announces that John Chiplin, currently Non-Executive Chairman, is retiring from the Board for personal reasons. Chris Britten, currently a Non-Executive Director of the Company, will assume the role of Non-Executive Chairman of N4 Pharma with effect from 1 August 2023.
お知らせ • Jan 18N4 Pharma Plc Provides Oral Application UpdateN4 Pharma Plc provided an update on its ongoing Australian Research Council grant work with the University of Queensland, investigating the oral delivery of Nuvec® loaded with DNA. The Company has now completed two in vivo studies demonstrating that Nuvec loaded with OVA m-cherry DNA and encapsulated within an acid protective polymer can be dosed orally, penetrate the mucus layer and successfully express the OVA m-cherry locally in the intestine epithelial cells. In the first study Nuvec® was formulated together with the OVA and the whole formulation was coated with the polymer as a capsule. In the second study the nanoparticles, once loaded with OVA, were individually encapsulated with the polymer and administered via an oral gavage.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Chairman John Chiplin was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Oct 11Companies Like N4 Pharma (LON:N4P) Are In A Position To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Board Change • Apr 27Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman John Chiplin was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
分析記事 • Jul 06Here's Why We're Not Too Worried About N4 Pharma's (LON:N4P) Cash Burn SituationThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, N4 Pharma ( LON:N4P...
分析記事 • Mar 18Should Shareholders Have Second Thoughts About A Pay Rise For N4 Pharma Plc's (LON:N4P) CEO This Year?The underwhelming performance at N4 Pharma Plc ( LON:N4P ) recently has probably not pleased shareholders. The next AGM...
分析記事 • Mar 01Here's What We Think About N4 Pharma's (LON:N4P) CEO PayNigel Theobald has been the CEO of N4 Pharma Plc ( LON:N4P ) since 2017, and this article will examine the executive's...
お知らせ • Feb 25N4 Pharma Plc, Annual General Meeting, Mar 24, 2021N4 Pharma Plc, Annual General Meeting, Mar 24, 2021, at 10:00 Coordinated Universal Time.
お知らせ • Feb 13N4 Pharma plc Announces Notification of Intention to Grant PatentN4 Pharma Plc announced that the University of Queensland ("UQ") has been notified by the European Patent Office ("EPO") of its intention to grant a European Patent in relation to Nuvec® specifically in respect of its composition, particulate materials and methods for making the particulate materials (the "Patent"). N4 Pharma has the exclusive worldwide rights to Nuvec® for therapeutic uses in humans and animals. Having received the notification the next steps prior to formal grant will require UQ to confirm the particulars and translations with the EPO prior to publication of the grant after which the Patent will be validated on a country by country basis throughout Europe as determined by UQ and the Company. This process, resulting in the full grant of the Patent in each chosen territory, should take six to eight months.
分析記事 • Dec 07Companies Like N4 Pharma (LON:N4P) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. Indeed, N4 Pharma ( LON:N4P ) stock is...
お知らせ • Dec 04N4 Pharma plc Provides the Following Update on Its Ongoing Research Collaboration Agreement with Nanomerics LimitedN4 Pharma Plc announced to provide the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on 11 February 2020, the Company initiated the first phase of research to test the stability of different formulations of Nuvec® loaded with a well characterised plasmid DNA. The Company reported that, in addition to not degrading the plasmid DNA, which it announced on 5 November 2020, Nuvec® formulations that had been freeze dried and then stored for 14 days either at room temperature or at four degrees Celsius, showed no significant drop in vitro transfection capability following reconstitution compared to fresh formulations. In parallel to continued work on analysing stability duration, different formulations will now be chosen to move forward into phase two of the work programme testing the efficacy of the dried and reconstituted plasmid DNA in an in vivo antibody generation model.
